The model combination of StepCox[both] + plsRcox yielded ... to investigate the functional switch of malignant cells in the progression of MVI in hepatocellular carcinoma and its impact on the immune ...

The mixed model that integrated microvascular invasion ... that could be construed as a potential conflict of interest. HCC, Hepatocellular carcinoma; RFS, Recurrence-free survival; MVI, Microvascular ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

2025 — Scientists have successfully developed a gastric cancer model using 3D bioprinting technology and patient-derived cancer tissue fragments. This innovative model preserves the ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...

While there currently isn’t a cure for cancer, researchers are exploring several new treatments, including vaccines and gene editing, that could eventually change the face of cancer treatment.